文献速递心律失常血脂与心血管预防

心房颤动卒中预防:在更广泛数据宇宙中重新定义「真实世界数据」

Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe.
PubMed 文献 · Eur Heart J · 2018-01-01

该综述提出应基于数据来源、治疗分配方法和研究背景三个维度评估证据,而非简单划分真实世界数据与非真实世界数据。以房颤抗凝为例,使用真实世界数据的观察性研究可描述口服抗凝药临床实践,但一般不能用于比较疗效;治疗效应问题最好通过随机对照试验回答,仍需更多实用性随机对照试验比较不同抗血栓药物预防房颤血栓事件。

要点

  • 真实世界数据仅指数据来源,研究设计、治疗分配和临床背景需分开评估。
  • 观察性真实世界数据研究可描述房颤口服抗凝药使用情况,但一般不能声称比较疗效。
  • 治疗效应问题最好通过随机对照试验回答,需更多实用性随机对照试验比较抗血栓药。

核心结论

  • 将证据分为真实世界与非真实世界仅是大框架的一个要素,应基于数据来源、治疗分配方法和研究背景评估证据。
  • 使用真实世界数据的观察性研究可用于描述口服抗凝药在房颤临床实践中的使用,但一般不能用于比较治疗效应。
  • 房颤抗血栓治疗效应问题最好通过随机对照试验回答,仍需更多实用性随机对照试验比较不同抗血栓药物预防血栓事件。

研究设计与样本

  • 综述,以房颤抗凝为视角,描述观察性与非观察性研究、涉及真实世界数据与非真实世界数据研究的优缺点。

主要发现

  • 证据评估框架包含数据来源、治疗分配方法(干预是否按方案分配或仅观察实践使用)和研究背景(总体研究设计)。
  • 真实世界数据指主要为非研究目的收集的数据,如保险理赔数据或电子健康记录,无论研究设计如何。
  • 分离研究设计、数据来源和背景可平行评估研究能否支持因果推断,以及研究人群和临床背景是否反映临床实践。

临床怎么用

  • 解读房颤抗凝证据时,应区分数据来源、治疗分配方法和研究背景,避免将观察性真实世界数据研究误用于比较疗效结论。
  • 描述口服抗凝药临床实践可使用真实世界数据观察性研究,比较治疗效应应优先参考随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Real-world data (RWD) has been defined as data generated outside of traditional randomized clinical trials (RCTs). Though RWD has received increasing attention from regulatory authorities and professional societies, dividing evidence into that derived from 'real-world' vs. 'non-real-world' sources provides only one element of a much larger framework for evidence evaluation. Evidence should be evaluated on the source of the data, the method of treatment allocation (whether any intervention being evaluated was assigned or simply observed as used in practice) and the context in which the evidence was generated (overall study design). Under this framework, RWD refers only to data source, and a study incorporates RWD when it primarily uses data collected for non-research purposes, such as insurance claims data or the electronic health record, regardless of study design. Separation of study design, data source, and context enables parallel evaluation of two critical elements: (i) whether a study can support claims of causal inference, which can be assured with a high degree of confidence only in studies where patients are assigned treatments by protocol; and (ii) whether the study population and clinical context mirror clinical practice, a strength of observational studies using data from clinical practice or administrative claims. In this review, we describe the strengths and weaknesses of observational and non-observational studies, and studies involving RWD and non-RWD, through the lens of anticoagulation for atrial fibrillation (AF). Observational studies employing RWD are useful for describing how oral anticoagulants are used in clinical practice, but generally cannot be used to make claims regarding comparative treatment effects. Questions regarding treatment effect generally are best answered through an RCT, and additional pragmatic RCTs are needed to compare different antithrombotic agents for the prevention of thrombotic events in AF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Fanaroff AC, Steffel J, Alexander JH, et al. Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe. Eur Heart J. 2018. PMID: 29688403. doi:10.1093/eurheartj/ehy236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。